Immunotherapy for the Treatment of Multiple Myeloma

Publication Date: July 12, 2020

Last Updated: March 14, 2022

Panel recommendations

Dara is FDA-approved and the panel recommends its use in the following settings:

In combination with lenalidomide and dexamethasone (D-Rd)in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with RRMM who have received at least one prior therapy.
In combination with bortezomib, melphalan, and prednisone (D-VMP) in newly diagnosed patients who are ineligible for autologous stem cell transplant.
In combination with bortezomib, thalidomide, and dexamethasone (D-VTD) in newly diagnosed patients who are eligible for autologous stem cell transplant.
In combination with bortezomib and dexamethasone (D-Vd) in patients who have received at least one prior therapy.
In combination with pomalidomide and dexamethasone (D-Pd)in patients who have received at least two prior therapies including lenalidomide and a PI.
As monotherapy, in patients who have received at least three prior lines of therapy including a PI and an IMiD or who are double-refractory to a PI and an IMiD.